Categories
Change Password!
Reset Password!
This assessment was carried out for characterizing the clinical backgrounds associated with the safety and efficacy of lubiprostone, an apical type 2 chloride channel activator.
Lubiprostone was effective for male patients
suffering from chronic constipation, and hypertension appears to be the
protective factor for nausea.
This assessment was carried out for
characterizing the clinical backgrounds associated with the safety and efficacy
of lubiprostone, an apical type 2 chloride channel activator.
The study included
participants with chronic constipation who were prescribed lubiprostone. With
the aid of electronic medical records, the safety and efficacy of lubiprostone
were retrospectively evaluated.
Overall, 155 participants (76 males, and mean age 69) were examined. Lubiprostone was noted to be effective in 74 people (47.8%). Discontinuation due to noxious effects occurred in 34 people (21.9%), including abdominal discomfort/pain, diarrhea, and nausea in 3, 12, and 16 people, respectively.
The efficacy was substantially linked with calcium channel
blockers, gender, age, antipsychotics, body mass index (BMI), diabetes
mellitus, and hypertension. In multivariate assessment, the efficacy was
considerably linked with men (odds ratio [OR], 3.21) and BMI (OR, 1.14). Nausea
occurrence was greater in people under 65 years old, and hypertension was found
to be an important protective factor for nausea.
For male patients having chronic constipation,
lubiprostone can effectively alleviate the symptoms of chronic constipation.
Scandinavian Journal of Gastroenterology
Evaluation of efficacy and safety of lubiprostone in patients with chronic constipation
Yukiko Handa et al.
Comments (0)